Scholarlink

Background <p>Pilonidal Sinus Disease (PSD) is an acquired inflammatory condition with no standard treatment. We evaluated our initial experience with Pediatric Endoscopic Pilonidal Sinus Treatment (PEPSiT).</p> Methods <p>We retrospectively reviewed all PEPSiT cases from May 2021–January 2025. Data collected included demographics, presentation, comorbidities, BMI, surgical time, anesthesia, hospital stay, complications, healing, recurrence, and follow-up (median, range).</p> Results <p>Thirty-two patients (18 males) underwent PEPSiT, median age 15 years (11–18), BMI 26.6&#xa0;kg/m² (16.7–51.6). None had prior surgery for PSD. Three had comorbidities (two with type 1 diabetes, one with Hemophilia B). Median operative time was 39&#xa0;min (19–58). All were day surgery procedures; 28 under sedation/local and 4 under general anesthesia. Median healing was 3 months (1–24). Complications included one granuloma (treated with silver nitrate) and one hematoma. All resumed normal activities the next day. Median follow-up was 9 months (1–52). Three recurrences were successfully treated with redo-PEPSiT.</p> Conclusion <p>Our outcomes suggest that PEPSiT is a safe, effective option for PSD. However, larger prospective studies are needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advancing pilonidal disease care through pediatric endoscopic treatment (PEPSiT): early insights

  • 期刊论文

  • 发表日期：

    2026年2月27日

查看全文
  • Maziar Fazel Darbandi,
  • Mackenzie Hoy,
  • Giuseppe Retrosi

摘要

Background

Pilonidal Sinus Disease (PSD) is an acquired inflammatory condition with no standard treatment. We evaluated our initial experience with Pediatric Endoscopic Pilonidal Sinus Treatment (PEPSiT).

Methods

We retrospectively reviewed all PEPSiT cases from May 2021–January 2025. Data collected included demographics, presentation, comorbidities, BMI, surgical time, anesthesia, hospital stay, complications, healing, recurrence, and follow-up (median, range).

Results

Thirty-two patients (18 males) underwent PEPSiT, median age 15 years (11–18), BMI 26.6 kg/m² (16.7–51.6). None had prior surgery for PSD. Three had comorbidities (two with type 1 diabetes, one with Hemophilia B). Median operative time was 39 min (19–58). All were day surgery procedures; 28 under sedation/local and 4 under general anesthesia. Median healing was 3 months (1–24). Complications included one granuloma (treated with silver nitrate) and one hematoma. All resumed normal activities the next day. Median follow-up was 9 months (1–52). Three recurrences were successfully treated with redo-PEPSiT.

Conclusion

Our outcomes suggest that PEPSiT is a safe, effective option for PSD. However, larger prospective studies are needed.